Ranbaxy Subsidiary in Rs 605 Crore Deal to Supply Anti-HIV Drugs in SA

India’s largest drug maker, Ranbaxy Laboratories has announced that its South African joint venture, Sonke Pharmaceuticals has won a mega deal worth Rs 605 crore to supply anti-HIV drugs in the country. Sonke Pharmaceuticals is a joint venture started by Ranbaxy Ltd and Community Investment Holdings (CIH) with Ranbaxy holding a majority 70 percent stake in the company. Ranbaxy revealed that the order was part of a bigger anti-retroviral (ARV) tender floated by the South African government and amounts to around 913.5 million rand.

Ranbaxy went on to confirm that some of the drugs will be manufactured locally while the remaining will be manufactured at Ranbaxy's facilities in India. The Managing Director of the company, Arun Sawhney said that Ranbaxy was pleased to be awarded with the order and is committed to bringing in quality medicines into the country.

“We are humbled to be given this responsibility to produce, supply and distribute affordable ARVs in South Africa. As a socially responsible global pharmaceutical company, we are committed to the cause of alleviating the suffering due to HIV AIDS and to bring high quality medication to those who need it the most”, he said.



Source-Medindia